Increasing research and development activities for identifying potential uses of recombinant human endostatin is expected to propel growth of the market. For instance, according to a paper published in the journal Nature, September 2015, a study was conducted to evaluate effects of recombinant human endostatin in combination with radiotherapy for treating esophageal squamous cell carcinoma and to discover its potential mechanisms. These findings suggested that recombinant human endostatin is a potential anti-angiogenic agent in esophageal squamous cell carcinoma mainly when combined with radiotherapy.
Free Request Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/2262
Furthermore, according to National Center for Biotechnology Information (NCBI) January 2017, recombinant human endostatin in combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) may aid in treatment of Angioimmunoblastic T Cell Lymphoma (AITL), a form of Peripheral T Cell Lymphoma (PTCL). Such novel therapies for PTCL treatment are immediately desired to improve the outcomes of patients with this disease. These factors are expected to propel growth of the recombinant human endostatin market.
North America is expected to hold dominant position in the global recombinant human endostatin market over the forecast period, owing to increasing prevalence of cancer in the U.S. For instance, According to a report by the Centers for Disease Control and Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S. in 2015 and the number is expected to reach to 1,735,350 in 2018.
Furthermore, Asia Pacific is projected to witness significant growth in the global recombinant human endostatin market during forecast period, owing to increasing number of clinical trials for recombinant human endostatin. For instance, the PLA General Hospital in China is undertaking clinical phase II study for recombinant human endostatin combination with radiotherapy for the treatment of Hepatocellular Carcinoma (HCC). The study started in January 2017 and is estimated to complete in December 2019.
Moreover, Yun-fei Xia University, in China is undergoing clinical phase II study using chemotherapy and Endostar (endostatin). Endostar is administered as an intravenous infusion for the treatment of refractory nasopharyngeal carcinoma. The study started in July 2015 and is expected to complete in December 2020.
Increasing challenges in significant production of recombinant human endostatin is expected to hinder the market growth. For instance, in April 2017, according to a National Center for Biotechnology Information (NCBI) report, tumor treatment needs large quantities of biologically active recombinant human endostatin, which in turn requires production of large quantities of recombinant human endostatin. This process is difficult as it based on recombinant DNA technology and also have low success rates for the treatment of cancer. Furthermore, the cost of recombinant human endostatin is high and it has short half-life. Endostatin is unstable since, endostatin-purification process may denature its structure and the resultant yields may be low.
For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/ongoing-insight/recombinant-human-endostatin-market-2262
Key players operating in the global recombinant human endostatin market include, Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG.